Development and characterization of AXT@metal-organic framework: A biocompatible, pH-responsive nanocarrier for targeted axitinib delivery in MCF-7 cancer cells
Annales Pharmaceutiques Françaises · 2026
DOI: 10.1016/j.pharma.2025.08.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annales Pharmaceutiques Françaises, 2026. Verfasst von Jayvadan K Patel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Viesain Pharma, LLC, Atlanta, GA, United States; Faculty of Pharmacy, Nootan Pharmacy College, Sankalchand Patel University, Visnagar, Gujarat, India. Hauptthemen laut MEDLINE: Metal-Organic Frameworks, Antineoplastic Agents, Drug Carriers, Axitinib. Die Arbeit nennt 44 Literaturangaben.
Abstract (Originalsprache)
Cancer remains a major global health challenge, characterized by low survival rates and significant side effects from conventional treatments. The metal-organic frameworks (MOFs) offer distinctive features that make them highly suitable for medical innovations. This study presents the development of MOFs as nanocarriers for the anticancer drug axitinib (AXT) to address these issues. Specifically, the MOFs were composed of titanium isopropoxide as metal ions and terephthalic acid as ligands, synthesized via a hydrothermal approach. The pH-responsive Ti-MOF was designed to enhance targeted drug delivery and minimize AXT side effects. The Ti-MOF was analyzed through various techniques, including UV-Vis spectroscopy, Fourier Transform Infrared (FTIR) spectroscopy, Scanning Electron Microscopy coupled with Energy Dispersive X-ray (SEM-EDX), zeta potential analysis, particle size measurement, Raman spectroscopy, and thermo gravimetric analysis (TGA). In vitro drug release studies at 37°C demonstrated that these porous carriers significantly slowed the release of AXT under neutral conditions, with only 4.5% to 8.0% released, mimicking normal tissue environments. In contrast, under acidic conditions (i.e., at pH 5), which simulates the acidic conditions of cancerous tissues, the release of AXT increased substantially, reaching 76% to 78% after 12h, While staying low at 8.0% to 9.5% at pH 7.4, this pH-sensitive release pattern results from the increased dissolution of the MOF material in acidic environments. This characteristic makes it a promising approach for targeted cancer therapy. The design of these MOF-based nanocarriers underscores their potential to enhance the precision and effectiveness of anticancer treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Viesain Pharma, LLC, Atlanta, GA, United States; Faculty of Pharmacy, Nootan Pharmacy College, Sankalchand Patel University, Visnagar, Gujarat, India.
- Faculty of Pharmacy, Nootan Pharmacy College, Sankalchand Patel University, Visnagar, Gujarat, India.
- Department of Pharmaceutical Chemistry, H.R. Patel Institute of Pharmaceutical Education and Research, Shirpur 425405, Dhule (MS), India.
- Faculty of Pharmacy, Nootan Pharmacy College, Sankalchand Patel University, Visnagar, Gujarat, India; Department of Pharmaceutical Chemistry, H.R. Patel Institute of Pharmaceutical Education and Research, Shirpur 425405…
Zitieren
APA
Patel, J. K., Shah, U. A., Patil, P. O., & Patil, J. H. (2026). Development and characterization of AXT@metal-organic framework: A biocompatible, pH-responsive nanocarrier for targeted axitinib delivery in MCF-7 cancer cells. Annales Pharmaceutiques Françaises. https://doi.org/10.1016/j.pharma.2025.08.004
Vancouver
Patel JK, Shah UA, Patil PO, Patil JH. Development and characterization of AXT@metal-organic framework: A biocompatible, pH-responsive nanocarrier for targeted axitinib delivery in MCF-7 cancer cells. Annales Pharmaceutiques Françaises. 2026. doi:10.1016/j.pharma.2025.08.004
BibTeX
@article{Patel2026,
author = {Patel, Jayvadan K and Shah, Ujashkumar A and Patil, Pravin O and Patil, Jitendra H},
title = {Development and characterization of AXT@metal-organic framework: A biocompatible, pH-responsive nanocarrier for targeted axitinib delivery in MCF-7 cancer cells},
journal = {Annales Pharmaceutiques Françaises},
year = {2026},
doi = {10.1016/j.pharma.2025.08.004}
}
EUVIMED